



**M3 Wake Research to be Among the First Sites to Conduct
Moderna's COVID-19 Vaccine Study in the US**

M3 Inc. (Headquarter: Tokyo, Japan; CEO: Itaru Tanimura; URL: <https://corporate.m3.com/>; "M3," below) has announced that its subsidiary, M3 Wake Research, Inc. ((Headquarter: USA; CEO: Dr. Ella Grach; <https://wakeresearch.com/>; "M3 Wake," below) will be among the first sites to enroll patients for Moderna's COVID-19 vaccine clinical study.

M3 Wake's Raleigh, North Carolina clinical trial site was selected as one of the first sites to conduct Moderna's COVID-19 vaccine study, and that Vice President Mike Pence will visit the site on July 29, 2020, to mark the beginning of the Phase-III trial.

Additionally, M3 Wake Research will enroll patients at several sites across the United States, and has already contracted with several companies for COVID-19 vaccines, treatments, prophylaxis, and diagnostic testing, and more projects are in the pipeline.

M3 Wake Research, a fully owned subsidiary of M3, Inc. has seen a surge in COVID-19 related clinical research studies.

About M3 Group:

M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (jp:2413) and M3 Wake Research is a fully owned subsidiary of M3, Inc. The M3 Group operates in Japan, US, Asia, and Europe with over 5.8 million physician members globally via its physician websites such as mdlinx.com, m3.com, Vidal.fr, doctors.net.uk, medigate.net and medlive.cn. M3 Group provides services to healthcare and the life science industry. In addition to clinical research, these services include medical education, ethical drug promotion, physician recruitment, market research, and clinical decision support systems. M3 has offices in Tokyo, Raleigh, NC, Fort Washington PA, Dallas, St Louis, New York, Oxford, London, Paris, and Seoul.